杜仲叶提取物对大鼠高脂性脂肪肝的实验观察

目的：通过建立高脂血症脂肪肝动物模型,探讨杜仲叶醇提取物（alcohol extractive of Folium Eucommiae,AEFE）对脂肪肝的防治作用。方法：高脂饮食8周加维生素D36×10^5IU/kg分3d腹腔注射,建立大鼠高脂血症脂肪肝动物模型。各给药组从造模第3周开始分别灌胃给予洛伐他汀（4mg·kg^-1·d^-1）、AEFE（70、140和420mg·kg^-1·d^-1）,共给药6周。各组每天灌服等量生理盐水,灌胃容积为0.5mL/100g体重。结果：AEFE用药6周后显示,各剂量组血清胆固醇、甘油三酯和游离脂肪酸、谷丙转氨酶和谷草转氨酶均较模型组明显降低（P〈0.05）,肝组织丙二醛含量降低和超氧化物歧化酶活性升高,肝脂肪变性和炎症反应减轻,尤以中剂量组作用最明显（P〈0.01）。AEFE对肝内肿瘤坏死因子-α浓度无明显影响。结论：AEFE改善高脂性大鼠肝脏脂肪变性,此作用可能与其降血脂、抗氧化损伤有关。

Experimental Observation of Alcohol Extractive of Folium Eucommiae on the Rats with Hyperlipidemia Fatty Liver

Objective.. To investigate the effects of alcohol extractive of Folium Eucommiae （AEFE） on the rats with hyperlipidemia fatty liver. Methods： Fatty liver model was established by feeding SD male rats with hyperlipid feed and vitamin D3 administration （6 ×10^5 IU/kg by intraperitoneal injected on 3 successive days） for 8 weeks. AEFE （70, 140 and 420 mg·kg^-1·d^-1,ig） was given for 6 weeks and was compared with lovastatin （4 mg·kg^-1·d^-1）. Results： Compared with model group, AEFE not only decreased the elevations of levels in total cholesterols （mmol/L） （4.63±1.19 vs 2.54±0.58, 1.87±0.18 and 1.96±0.81）, triglyceride （mmol/L） （3.16±0.57 vs 1.18±0.24, 0.98±0.17 and 0. 76±0.11）, free fatty acids （mmol/L） （654.73±101.52 vs 505.38±89.64, 416.98±108.34 and 400. 854±93.56）, alanine aminotrans-ferase （u/L） （56.32±6.11 vs 40.49±5.27, 31.43±5.14 and 29.17±4.51）, aspartate aminotransferase （u/L） （62.54±5.79 vs 48.29±4.68, 32.04±3.15 and 32.33±4.04） in serum and malondialdehyde （nmol/mg pro） （7.31±0.79 vs 6.05±0.63, 4.98±0.72 and 5.72±0.82） in hepatic tissue significantly, but also reversed the decrease in superoxide dismutase activity （U/rag pro） （39.44±4.21 vs 47.03±6.16, 53.17±6.71 and 50.48±5.24） in hepatic tissue. At the same time, AEFE obviously ameliorated the pathologic changes on fat liver, but did not influence the levels of tumor necrosis factor-α in hepatic tissue. Conclusion： AEFE has a protective effect on hyperlipidemia fatty liver and its protection may involve in regulating plasma lipid metabolic disorder and enhancing anti-oxidant capacity.